Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib (ARQ 197) and shRNA c-MET knockdown.

@article{Previdi2012BreastCB,
  title={Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib (ARQ 197) and shRNA c-MET knockdown.},
  author={Sara Previdi and Giovanni Abbadessa and Francesca Dal{\`o} and Dennis S France and Massimo Broggini},
  journal={Molecular cancer therapeutics},
  year={2012},
  volume={11 1},
  pages={214-23}
}
Breast cancer exhibits a propensity to metastasize to bone, resulting in debilitating skeletal complications associated with significant morbidity and poor prognosis. The cross-talk between metastatic cancer cells and bone is critical to the development and progression of bone metastases. We have shown the involvement of the HGF/c-MET system in tumor-bone interaction contributing to human breast cancer metastasis. Therefore, disruption of HGF/c-MET signaling is a potential targeted approach to… CONTINUE READING
35 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 35 extracted citations

Similar Papers

Loading similar papers…